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The accuracy of LiPA 2.0 for hepatitis C virus 1 (HCV-1) subtype classification was analyzed. LiPA 2.0 genotype results from 101
HCV-1-infected patients were compared to genotype findings determined by direct core sequencing. Eleven (11%) samples were
misclassified. Given the influence of the HCV-1-subtype in the anti-HCV therapy response, an alternative classificationmethod
is warranted.
The effect of the hepatitis C virus (HCV) genotype 1 subtype onthe response to treatment can be dramatic for some direct
antiviral agent (DAA)-containing regimens (1–9). This is the case
for simeprevir, a DAA recently approved for clinical use, that in
combination with pegylated interferon and ribavirin (peg-IFN/
RBV) has a lower sustained virological response (SVR) rate for
subtype 1a than for 1b (2). Simeprevir plus peg-IFN/RBV treat-
ment achieves rates of SVR similar to those for peg-IFN/RBV
treatment in HCV-1a-infected patients who present the viral vari-
ation Q80K. This variation is frequent in the HCV-1a subtype, but
it is not found in HCV-1b (2, 5). Similarly, daclatasvir plus peg-
IFN/RBV treatment also achieves higher SVR rates among HCV-
1b-infected patients than among HCV-1a-infected individuals
(4). For interferon-free regimens, DAA combinations such as asu-
naprevir plus daclatasvir may only be indicated for subtype 1b,
because of high relapse rates observed among patients with sub-
type 1a (3, 4). Because of these, accurate subtyping of HCV geno-
type 1-infected patients is needed for those who are candidates for
DAAs.
Sequencing of specific HCV genome regions with subsequent
phylogenetic analysis is considered the gold standard of HCV
genotyping (10). However, it includes several complex techniques
and is time consuming. For these reasons, LiPA 2.0 is currently
one of the most widely used genotyping assays. However, several
studies have reported HCV genotyping errors using this commer-
cial method (11–13). Those studies were not designed to evaluate
the frequency of HCV-1 subtyping misclassifications, and they
included few HCV-1-infected patients. Therefore, due to the high
prevalence of HCV-1 infections in western countries and the im-
portance of correct subtyping in clinical decisions, the accuracy of
this method for HCV-1 subtyping needs to be evaluated in larger
samples. For these reasons, we aimed to evaluate the accuracy of
LiPA 2.0 for classifying HCV-1 by subtypes.
This study was performed according to the ethical guidelines of
the 1975 Declaration of Helsinki, and it was approved by the ethics
committee of the Hospital Universitario de Valme (Seville, Spain).
The first 110 consecutive patients starting from October 2001,
who received a course of peg-IFN/RBV treatment in our hospital
and who were infected with HCV-1, according to the LiPA 2.0
determination, were selected. All of them were Caucasian with a
median age (quartile 1 to quartile 3) of 42 years (range, 39 to 46
years). Among the patients, 82 (81%) were male, and 48 (47.5%)
were infected with HIV.
To determine the HCV-1 subtype, we analyzed the entire core
genetic sequence. This region is more conserved than those tradi-
tionally used for HCV genotyping (NS5B or core/E1) and allows
higher amplification rates (13, 14). The core region was amplified
by nested PCRs. The first PCR was performed with 5 l of cDNA
using primers 1 and 2 (Table 1). For the second PCR, 4 l of the
first PCR product and primers 3 and 4 (Table 1) were used. For
those samples that were not amplified with this protocol, primers
1 and 5 for the LiPA 2.0-identified subtype 1a or primers 1 and 4
for subtype 1b were used to perform the external PCR and then
primers 6 and 7 (1a) or 8 (1b) were used in the internal PCR (Table
1). The nested PCR products were bidirectionally sequenced using
standard capillary electrophoresis techniques. ClustalW2 software
(www.ebi.ac.uk/Tools/msa/clustalw2/) was used for alignment of
the forward and reverse sequenced strains to obtain consensus
sequences.
As the genotyping method, we analyzed the evolutionary his-
tory, which was inferred by using the maximum likelihood
method based on the general time reversible model. Evolutionary
analyses were conducted in MEGA5 software (15). The initial
tree(s) for the heuristic search was obtained by applying the neigh-
bor-joining method to a matrix of pairwise distances estimated
using the maximum composite likelihood (MCL) approach (15).
A discrete gamma distribution was used to model the evolutionary
rate differences among sites (4 categories [G, parameter 
0.3742]). The analysis involved 110 sequences, including the se-
quences from patient samples and those selected as references. In
the final data set, there were a total of 573 base pair positions
corresponding to the complete core region for each sample.
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Successful sequencing and genotyping were obtained in 101
(91.8%) patients. The 9 (8.2%) samples that were not amplified
had a viral load of3 log IU/ml.
According to LiPA 2.0, 58 (57.4%) samples were identified as
HCV-1a, and the remaining 43 (42.6%) were identified as HCV-
1b. By the sequence-based method, 67 (66.3%) samples were clas-
sified as genotype 1a, 33 (32.7%) samples were classified as 1b, and
1 (1%) was classified as 4d (Table 2). The overall Cohen kappa
index obtained was 0.773 (95% confidence interval, 0.647 to
0.900). The proportion of patients with misclassified HCV-1 sub-
types was 11%. All HCV-1 subtype misclassifications were ob-
served among individuals identified by LiPA 2.0 as the HCV-1b
subtype. Thus, 10 (23%) patients classified as HCV-1b by LiPA 2.0
were identified as HCV-1a by sequencing methods (Table 2). The
sensitivity, specificity, positive predictive value, and negative pre-
dictive value for HCV-1b subtyping by LiPA 2.0 were 1, 0.85, 0.77,
and 1, respectively. The corresponding numbers for HCV-1a sub-
typing were 0.85, 0.97, 0.98, and 0.77, respectively.
This is the largest study, to our knowledge, that has analyzed
the accuracy of HCV-1 subtype identification by LiPA 2.0. The
study of Avó et al. (11) included a total of 31 HCV-1 samples (of
them, only 7 were 1b), whereas in the study of Bouchardeau et al.
(12), there were a total of 62 HCV-1 samples and only 21 of them
were 1b. In a similar study, HCV-1a-infected patients were not
included because of the HCV genotype distribution (13).
In conclusion, our results show that the LiPA 2.0 assay is not an
adequate tool for subtyping HCV genotype 1. This genotyping
method has subtyping failures, and it is prone to errors with HCV
subtype 1b. Because the HCV subtype 1 misclassification might
lead to inadequate treatment associated with a high likelihood of
nonresponse, more accurate genotyping methods than LiPA 2.0
should be used.
Nucleotide sequence accession numbers. The sequences ob-
tained in this study were submitted to GenBank under accession
numbers KF060663 to KF060714 and KJ739737 to KJ739786.
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